Protagenic Therapeutics, Incnew

Protagenic Therapeutics, Inc. has terminated its acquisition of Phytanix Bio and settled related litigation, paying $310,000 in the process.

Protagenic Therapeutics, Inc. announced its common stock and warrants will be delisted from Nasdaq and begin trading on the over-the-counter market due to non-compliance with listing rules.

Protagenic Therapeutics received a Nasdaq delisting notice due to insufficient stockholders' equity and delayed financial reporting.

Jennifer Chao has resigned from the Board of Directors of Protagenic Therapeutics, Inc., effective November 3, 2025, with no reported disagreements.

Protagenic Therapeutics, Inc. has filed a lawsuit in Delaware Chancery Court seeking to rescind its acquisition of Phytanix Bio, Inc. or obtain damages.

Protagenic Therapeutics, Inc. filed an amendment to its Form 8-K/A to update the auditor's consent related to the Phytanix Bio acquisition.

Protagenic Therapeutics reported a significant increase in net loss for Q2 2026, implemented a major restructuring plan, and faces ongoing Nasdaq compliance issues despite a recent reverse merger.

Protagenic Therapeutics reports a significant net loss in Q1 2026 following a reverse merger, announces a major restructuring, and faces ongoing Nasdaq compliance issues.

Protagenic Therapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional financing.

Protagenic Therapeutics reported a net loss of $640,785 for the third quarter of 2024, alongside updates on their clinical trial for PT00114 and a recent private placement.

Protagenic Therapeutics' Q2 2024 report reveals increased research and development expenses, leading to a larger operating loss and raising concerns about the company's ability to continue as a going concern.

Protagenic Therapeutics experienced a significant increase in operating losses during the first quarter of 2024, primarily due to increased research and development expenses.

Protagenic Therapeutics, Inc. files its annual report on Form 10-K, detailing its financial results for the year ended December 31, 2024, and providing an update on its clinical development programs and corporate strategy.

Protagenic Therapeutics has filed an amendment to its annual report, highlighting the correction of an error and providing updates on its clinical trial progress for PT00114.

Protagenic Therapeutics files an amendment to its annual report to include an omitted certification, while also providing updates on its clinical trial progress and financial status.

Protagenic Therapeutics' annual 10-K filing details its capital structure, ongoing clinical trials, and strategic focus on developing treatments for stress-related neuropsychiatric disorders.

Garo H Armen, EXEC. CHAIR & PRINCIPAL OFF. and a Director of Protagenic Therapeutics, Inc.new, purchased 26,291 shares of common stock on July 30, 2026 for $0.18 per share.

Director Timothy R. Wright acquired options for 21,250 shares of Protagenic Therapeutics (PTIX) common stock on March 25, 2024.

Robert Benjamin Stein, a director of Protagenic Therapeutics, acquired options for 75,000 shares of PTIX common stock on March 25, 2024.

Director Khalil Barrage acquired 22,500 options in Protagenic Therapeutics (PTIX) on March 25, 2024, at an exercise price of $1.74.

Jennifer Buell, a director at Protagenic Therapeutics, acquired options to purchase 75,000 shares of PTIX common stock on March 25, 2024.

Garo H. Armen, Executive Chairman of Protagenic Therapeutics, acquired 250,000 stock options on March 25, 2024, according to a Form 4 filing.

Protagenic Therapeutics announces its virtual annual meeting on December 31, 2025, seeking stockholder ratification for a new independent accounting firm and detailing significant board composition changes.

Protagenic Therapeutics and Phytanix Bio combine in an all-stock transaction to form Phytanix, Inc., a neuroactive biopharmaceutical company with a diverse pipeline.

Protagenic Therapeutics is asking stockholders to approve a reverse stock split to maintain compliance with Nasdaq's minimum bid price requirement and potentially increase investor interest.

Protagenic Therapeutics issues a supplement to its proxy statement to correct an error in the record date and the number of outstanding shares.

Protagenic Therapeutics is holding a virtual annual meeting on February 21, 2025, to vote on key proposals including director elections, option repricing, warrant issuance approval, and an equity incentive plan amendment.

Protagenic Therapeutics is registering the resale of 5,844,885 shares of common stock by selling stockholders, including shares issued in a recent private placement and those issuable upon exercise of warrants.

Bigger Capital Fund, LP and its affiliates have reported a complete divestment of their beneficial ownership in Protagenic Therapeutics, Inc., now holding 0% of common stock.

Bigger Capital Fund L.P., along with its general partner Bigger Capital Fund GP, LLC and managing member Michael Bigger, has disclosed a beneficial ownership of 5.75% in Protagenic Therapeutics, Inc., totaling 50,000 shares of common stock.

Armistice Capital, LLC and Steven Boyd have reported a 3.41% beneficial ownership stake in Protagenic Therapeutics, Inc., holding 240,000 shares as of December 31, 2024, as a passive investment.